Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ)
CNY 4.77
(-0.83%)
CNY 4.77
(-0.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.82 Billion CNY | -5.4% |
| 2022 | 1.93 Billion CNY | 4.94% |
| 2021 | 1.84 Billion CNY | 29.83% |
| 2020 | 1.41 Billion CNY | 89.89% |
| 2019 | 746.59 Million CNY | 24.72% |
| 2018 | 598.61 Million CNY | 15.51% |
| 2017 | 518.23 Million CNY | 19.41% |
| 2016 | 433.99 Million CNY | 26.56% |
| 2015 | 342.9 Million CNY | 175.02% |
| 2014 | 124.68 Million CNY | -9.95% |
| 2013 | 138.46 Million CNY | 64.44% |
| 2012 | 84.2 Million CNY | -32.47% |
| 2011 | 124.68 Million CNY | 91.57% |
| 2010 | 65.08 Million CNY | -41.0% |
| 2009 | 110.31 Million CNY | 20.13% |
| 2008 | 91.83 Million CNY | 26.53% |
| 2007 | 72.57 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.67 Billion CNY | -3.64% |
| 2024 Q3 | 1.63 Billion CNY | -2.35% |
| 2024 Q1 | 1.73 Billion CNY | -4.83% |
| 2023 Q1 | 2.25 Billion CNY | 16.91% |
| 2023 Q4 | 1.82 Billion CNY | -9.16% |
| 2023 FY | 1.82 Billion CNY | -5.4% |
| 2023 Q2 | 2.23 Billion CNY | -1.07% |
| 2023 Q3 | 2.01 Billion CNY | -9.96% |
| 2022 Q3 | 1.96 Billion CNY | 4.29% |
| 2022 FY | 1.93 Billion CNY | 4.94% |
| 2022 Q2 | 1.88 Billion CNY | 11.8% |
| 2022 Q4 | 1.93 Billion CNY | -1.88% |
| 2022 Q1 | 1.68 Billion CNY | -8.27% |
| 2021 Q3 | 1.46 Billion CNY | 0.44% |
| 2021 FY | 1.84 Billion CNY | 29.83% |
| 2021 Q1 | 1.49 Billion CNY | 5.66% |
| 2021 Q2 | 1.45 Billion CNY | -2.89% |
| 2021 Q4 | 1.84 Billion CNY | 25.97% |
| 2020 Q3 | 1.29 Billion CNY | 15.94% |
| 2020 Q4 | 1.41 Billion CNY | 9.59% |
| 2020 Q2 | 1.11 Billion CNY | 23.15% |
| 2020 Q1 | 906.01 Million CNY | 21.35% |
| 2020 FY | 1.41 Billion CNY | 89.89% |
| 2019 Q2 | 590.03 Million CNY | 3.59% |
| 2019 Q4 | 746.59 Million CNY | 17.74% |
| 2019 FY | 746.59 Million CNY | 24.72% |
| 2019 Q3 | 634.11 Million CNY | 7.47% |
| 2019 Q1 | 569.57 Million CNY | -4.85% |
| 2018 Q3 | 572.85 Million CNY | 14.83% |
| 2018 Q1 | 556.94 Million CNY | 7.47% |
| 2018 FY | 598.61 Million CNY | 15.51% |
| 2018 Q4 | 598.61 Million CNY | 4.5% |
| 2018 Q2 | 498.88 Million CNY | -10.42% |
| 2017 Q3 | 499.9 Million CNY | 7.54% |
| 2017 Q4 | 518.23 Million CNY | 3.67% |
| 2017 FY | 518.23 Million CNY | 19.41% |
| 2017 Q1 | 435.6 Million CNY | 0.37% |
| 2017 Q2 | 464.83 Million CNY | 6.71% |
| 2016 Q2 | 770.53 Million CNY | 133.55% |
| 2016 FY | 433.99 Million CNY | 26.56% |
| 2016 Q4 | 433.99 Million CNY | -31.79% |
| 2016 Q3 | 636.29 Million CNY | -17.42% |
| 2016 Q1 | 329.91 Million CNY | -3.79% |
| 2015 Q3 | 339.04 Million CNY | -9.52% |
| 2015 Q4 | 342.9 Million CNY | 1.14% |
| 2015 FY | 342.9 Million CNY | 175.02% |
| 2015 Q1 | 112.04 Million CNY | -10.14% |
| 2015 Q2 | 374.71 Million CNY | 234.44% |
| 2014 Q4 | 124.68 Million CNY | -3.94% |
| 2014 Q3 | 129.79 Million CNY | -23.79% |
| 2014 FY | 124.68 Million CNY | -9.95% |
| 2014 Q2 | 170.31 Million CNY | 21.94% |
| 2014 Q1 | 139.67 Million CNY | 0.87% |
| 2013 Q2 | 119.49 Million CNY | 13.01% |
| 2013 Q4 | 138.46 Million CNY | -37.23% |
| 2013 FY | 138.46 Million CNY | 64.44% |
| 2013 Q1 | 105.74 Million CNY | 25.58% |
| 2013 Q3 | 220.61 Million CNY | 84.62% |
| 2012 FY | 84.2 Million CNY | -32.47% |
| 2012 Q1 | 104.54 Million CNY | -16.15% |
| 2012 Q4 | 84.2 Million CNY | -14.78% |
| 2012 Q3 | 98.8 Million CNY | -10.63% |
| 2012 Q2 | 110.55 Million CNY | 5.75% |
| 2011 Q1 | 78.63 Million CNY | 20.82% |
| 2011 FY | 124.68 Million CNY | 91.57% |
| 2011 Q4 | 124.68 Million CNY | 71.71% |
| 2011 Q2 | 62.89 Million CNY | -20.02% |
| 2011 Q3 | 72.61 Million CNY | 15.45% |
| 2010 Q4 | 65.08 Million CNY | 0.0% |
| 2010 Q2 | 96.9 Million CNY | 0.0% |
| 2010 FY | 65.08 Million CNY | -41.0% |
| 2009 FY | 110.31 Million CNY | 20.13% |
| 2008 FY | 91.83 Million CNY | 26.53% |
| 2007 FY | 72.57 Million CNY | 0.0% |